uniQure Seeks to Find Elusive Market Success with Hemophilia B Gene Therapy

January 5, 2018

uniQure achieved a milestone when it won approval in Europe for Glybera, the first gene therapy approved in the Western World, but it later pulled it from the market because it wasn’t commercially viable. Now, it is advancing a gene therapy for the rare genetic clotting disorder hemophilia B through development. We spoke to Steve Zelenkofske, chief medical officer at uniQure, about what the company has learned from its experience with Glybera, what the data from its hemophilia B gene therapy has shown, and how its expecting to alter that therapy to make a more effective version that may provide an even greater response.


Stay Connected

Sign up for updates straight to your inbox.